avapro has been researched along with Recrudescence in 6 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The primary end-point was recurrence of AF." | 6.75 | Combination of irbesartan and amiodarone to maintain sinus rhythm in patients with persistent atrial fibrillation after rheumatic valve replacement. ( Cai, J; Feng, J; Ji, Q; Mei, Y; Sun, Y; Wang, X; Wusha, D; Xie, S, 2010) |
| "A substantial number of patients with lupus nephritis (LN) are refractory to conventional glucocorticoid (GC) treatment." | 5.39 | Successful treatment of class IV+V lupus nephritis with combination therapy of high-dose corticosteroids, tacrolimus and intravenous cyclophosphamide. ( Amano, K; Chino, K; Ito, T; Kato, H; Kondo, T; Kurasawa, T; Nagasawa, H; Nishi, E; Nishimura, K; Ogawa, H; Okuyama, A; Sakai, R; Shibata, A; Takei, H, 2013) |
| "Patients treated with amiodarone plus irbesartan had a lower rate of recurrence of atrial fibrillation than did patients treated with amiodarone alone." | 5.10 | Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. ( Bernal, E; Bueno, MG; Cabeza, P; Cano, JM; Cano, L; Madrid, AH; Marín, I; Moro, C; Peña, G; Rebollo, JM; Rodriguez, A, 2002) |
| "Study on the Effect of Irbesartan on Atrial Fibrillation Recurrence in Kumamoto (SILK study) is a prospective, multicenter, randomized, and open-label comparative evaluation of the effects of irbesartan and amlodipine on AF recurrence in hypertensive patients with AF who are scheduled to undergo catheter ablation or electrical cardioversion of AF." | 3.88 | Study on the Effect of Irbesartan on Atrial Fibrillation Recurrence in Kumamoto: Atrial Fibrillation Suppression Trial (SILK study). ( Fujimoto, K; Iwasa, A; Kaikita, K; Kajiwara, I; Koyama, J; Matsui, K; Matsumura, T; Morihisa, K; Morikami, Y; Ogawa, H; Tsujita, K; Tsunoda, R; Uemura, T; Yamabe, H, 2018) |
| "The primary end-point was recurrence of AF." | 2.75 | Combination of irbesartan and amiodarone to maintain sinus rhythm in patients with persistent atrial fibrillation after rheumatic valve replacement. ( Cai, J; Feng, J; Ji, Q; Mei, Y; Sun, Y; Wang, X; Wusha, D; Xie, S, 2010) |
| "A substantial number of patients with lupus nephritis (LN) are refractory to conventional glucocorticoid (GC) treatment." | 1.39 | Successful treatment of class IV+V lupus nephritis with combination therapy of high-dose corticosteroids, tacrolimus and intravenous cyclophosphamide. ( Amano, K; Chino, K; Ito, T; Kato, H; Kondo, T; Kurasawa, T; Nagasawa, H; Nishi, E; Nishimura, K; Ogawa, H; Okuyama, A; Sakai, R; Shibata, A; Takei, H, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haga, N | 1 |
| Nishie, W | 1 |
| Morita, Y | 1 |
| Mizuno, O | 1 |
| Ohguchi, Y | 1 |
| Shimizu, H | 1 |
| Yamabe, H | 1 |
| Kaikita, K | 1 |
| Matsumura, T | 1 |
| Iwasa, A | 1 |
| Koyama, J | 1 |
| Uemura, T | 1 |
| Morikami, Y | 1 |
| Tsunoda, R | 1 |
| Morihisa, K | 1 |
| Fujimoto, K | 1 |
| Kajiwara, I | 1 |
| Matsui, K | 1 |
| Tsujita, K | 1 |
| Ogawa, H | 2 |
| Kurasawa, T | 1 |
| Nagasawa, H | 1 |
| Nishi, E | 1 |
| Takei, H | 1 |
| Okuyama, A | 1 |
| Kondo, T | 1 |
| Nishimura, K | 1 |
| Sakai, R | 1 |
| Shibata, A | 1 |
| Chino, K | 1 |
| Ito, T | 1 |
| Amano, K | 1 |
| Kato, H | 1 |
| Ji, Q | 1 |
| Mei, Y | 1 |
| Wang, X | 1 |
| Feng, J | 1 |
| Wusha, D | 1 |
| Cai, J | 1 |
| Sun, Y | 1 |
| Xie, S | 1 |
| Madrid, AH | 1 |
| Bueno, MG | 1 |
| Rebollo, JM | 1 |
| Marín, I | 1 |
| Peña, G | 1 |
| Bernal, E | 1 |
| Rodriguez, A | 1 |
| Cano, L | 1 |
| Cano, JM | 1 |
| Cabeza, P | 1 |
| Moro, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Colchicine for the Prevention of Atrial Fibrillation Recurrence After Electrical Cardioversion of Persistent Atrial Fibrillation.[NCT02582190] | Phase 3 | 0 participants (Actual) | Interventional | 2017-12-02 | Withdrawn (stopped due to Investigational Medicinal Product Supplies) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for avapro and Recrudescence
| Article | Year |
|---|---|
Combination of irbesartan and amiodarone to maintain sinus rhythm in patients with persistent atrial fibrillation after rheumatic valve replacement.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Fibrillation; Biphenyl Co | 2010 |
Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study.
Topics: Adult; Aged; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2002 |
4 other studies available for avapro and Recrudescence
| Article | Year |
|---|---|
A case of idiopathic angioedema exacerbated by angiotensin receptor blocker administration.
Topics: Aged; Angioedema; Angiotensin II Type 1 Receptor Blockers; Humans; Irbesartan; Male; Recurrence | 2017 |
Study on the Effect of Irbesartan on Atrial Fibrillation Recurrence in Kumamoto: Atrial Fibrillation Suppression Trial (SILK study).
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Atrial Fibrillation; Biphenyl Compounds; Blood P | 2018 |
Successful treatment of class IV+V lupus nephritis with combination therapy of high-dose corticosteroids, tacrolimus and intravenous cyclophosphamide.
Topics: Adolescent; Antihypertensive Agents; Biphenyl Compounds; Cyclophosphamide; Cyclosporine; Drug Therap | 2013 |
[Sartan improves anti-arrhythmia therapy after cardioversion. Fewer recurrent fibrillation incidents].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biphenyl Compounds; Drug Therapy, Combinati | 2002 |